Skip to main content

Table 2 The summary of cases of invasive aspergillosis in ESKD patients

From: Invasive aspergillosis in the patient with focal segmental glomerulosclerosis initiating hemodialysis: a case report and mini-review

Age

Gender

Kidney diseases

Pulmonary complications

Other comorbidities

Pathogen

Site/clinical manifestation

Treatment (start timing if described)

Dosage of antifungals

Outcome

Reference

66

Male

ESKD from FSGS

Past NTM disease

None

Aspergillus spp.

Lung, intracranial

abscess

Described in the manuscript

Described in the manuscript

Discharge (day 380) and death one month later

This case

15

Male

CAPD, cause unknown (global sclerosis)

Not described

Not described

Aspergillus spp.

Intracranial hemorrhagic abscesses

L-AMB

Not described

Death (day 13)

[28]

55

Female

ESKD starting PD, cause reflux nephropathy

A smoker of 20 cigarettes per day

Not described

Aspergillus fumigatus

Lung

L-AMB (from day 3)

Not described

Death (day 3)

[29]

34

Male

HD

Past pulmonary tuberculosis

Type 1 DM

Not described

Lung (in a tuberculous cavity), laryngeal tissue mass

VRCZ

6 mg/kg every12 hours

Death (Two days later)

[15]

54

Female

HD

Not described

Type 2 DM

Not described

Rhino-sinusitis

The antifungals with surgical drainage

Not described

Unknown

[15]

49

Male

HD

Not described

long‐standing hypertension

Not described

submandibular swelling and lung

Caspofungin, oral VRCZ

Not described

Stable

[30]

  1. CAPD continuous ambulatory peritoneal dialysis; DM diabetes mellitus; ESKD end-stage kidney disease; FSGS focal segmental glomerulosclerosis; HD hemodialysis; L-AMB liposomal amphotericin B; NTM nontuberculous mycobacterial; PD peritoneal dialysis; and VRCZ voriconazole